ReviewClinical and molecular hepatology2019
Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.
Review in Clinical and molecular hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.Journal of gastroenterology · 2026Article
- Shrinking hemangiomas amid advancing cirrhosis: A report of 2 cases.Radiology case reports · 2026Article
- Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Multiphase Computed Tomography Scan Findings for Artificial Intelligence Training in the Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Interobserver Agreement of Expert Abdominal Radiologists.Diagnostics (Basel, Switzerland) · 2025Article
- Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection.European radiology · 2024Article
- Intra-patient and inter-observer image quality analysis in liver MRI study with gadoxetic acid using two different multi-arterial phase techniques.The British journal of radiology · 2024Article
- Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.European radiology · 2023Review
- Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre.Abdominal radiology (New York) · 2023Observational
- Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.Korean journal of radiology · 2022Review
- Article
- Article
- Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older.Annals of surgical treatment and research · 2021Article
- Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2021Article
- Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.Hepatology international · 2021Article
- Diagnosis of focal liver lesions with deep learning-based multi-channel analysis of hepatocyte-specific contrast-enhanced magnetic resonance imaging.World journal of gastroenterology · 2021Article
- Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.International journal of molecular sciences · 2021Article
- Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.Abdominal radiology (New York) · 2021Review
- Article
- Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadoxetic acid, a hepatocyte-specific magnetic resonance imaging (MRI) contrast agent, has emerged as an important tool for hepatocellular carcinoma (HCC) diagnosis. Gadoxetic acid-enhanced MRI is useful for the evaluation of earlystage HCC, diagnosis of HCC precursor lesions, and highly sensitive diagnosis of HCC. Furthermore, functional information provided by gadoxetic acid-enhanced MRI can aid in the characterization of focal liver lesions. For example, whereas lesions lack functioning hepatocytes appear hypointense in the hepatobiliary phase, preserved or enhanced expression of organic anion transporting polypeptides in some HCCs as well as focal nodular hyperplasia lead to hyperintensity in the hepatobiliary phase; and a targetoid appearance on transitional phase or hepatobiliary phase imaging can be helpful for identifying the histopathological composition of tumors. While gadoxetic acid-enhanced MRI may improve the sensitivity of HCC diagnosis and provide new insights into the characterization of focal liver lesions, there are many challenges associated with its use. This article reviews the pros and cons of HCC diagnosis with gadoxetic acid-enhanced MRI and discuss some clues in the radiological differentiation of HCC from HCC mimickers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.